Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Concomitant chemoradiation followed by repeat (dose-deescalated) irradiation has become standard of care in treating childhood diffuse intrinsic pontine glioma (DIPG) during first line treatment and at first progression. Progression after re-irradiation (re-RT) is in most cases symptomatic and either treated systemically with chemotherapy or new innovative approaches including targeted therapy. Alternatively, the patient receives best supportive care. Data on second re-irradiation in DIPG patients with second progression and good performance status are sparse. This is a case report of second short-term re-irradiation to shed further light on this option.
Methods: Retrospective case report of a 6-year-old boy with DIPG receiving a second course of re-irradiation (with 21.6 Gy) as part of an individual multimodal approach in a patient with very low symptom burden.
Results: The second course of re-irradiation was feasible and well tolerated. No acute neurological symptoms or radiation-induced toxicity occurred. Overall survival was 24 months after initial diagnosis.
Conclusion: A second course of re-irradiation can be an additional tool in patients with progressive disease after first- and second-line irradiation. It is unclear whether and to what extent it contributes to progression-free survival prolongation and if-since our patient was asymptomatic-progression-associated neurological deficits can be alleviated.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361911 | PMC |
| http://dx.doi.org/10.1007/s00066-023-02057-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long Term Outcomes after Re-Irradiation With Spine Stereotactic Body Radiation Therapy: Single Institutional Retrospective Experience.
Pract Radiat Oncol
September 2025
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.
Re-irradiation of spinal metastases using stereotactic body radiotherapy (SBRT) presents clinical challenges, with limited patient outcomes data to guide decision-making. We report a retrospective, single-institutional experience of 107 lesions treated in 91 patients. 88 (72%) lesions were initially irradiated with conventional radiotherapy (median equivalent dose of 33Gy to the target, interquartile range, IQR: 23-35 Gy) with a median time to re-irradiation of 12 months (IQR: 4-21 months).
View Article and Find Full Text PDFEvaluation of tattoo reliability in breast cancer re-irradiation.
Tech Innov Patient Support Radiat Oncol
September 2025
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Background: Tattoos help guide field placement in breast re-irradiation. This study evaluates the stability of medial tattoos in patients with prior breast radiotherapy (RT) to determine their reliability as surface markers.
Materials And Methods: We retrospectively identified patients who had breast/chest wall re-irradiation between January 2022 and December 2023 (RT) and prior breast RT (RT) at our institution.
Delta Changes in [F]FDG PET/CT Parameters Can Prognosticate Clinical Outcomes in Recurrent NSCLC Patients Who Have Undergone Reirradiation-Chemoimmunotherapy.
Biomedicines
July 2025
Department of Radiation Oncology, Paracelsus Medical University, SALK, Müllner Hauptstraße 48, A-5020 Salzburg, Austria.
: Stratification based on specific image biomarkers applicable in clinical settings could help optimize treatment outcomes for recurrent non-small cell lung cancer patients. For this purpose, we aimed to determine the clinical impact of positive delta changes (any difference above zero > 0) between baseline [F]FDG PET/CT metrics before the first treatment course and reirradiation. Forty-seven patients who underwent thoracic reirradiation with curative intent at our institute between 2013 and 2021 met the inclusion criteria.
View Article and Find Full Text PDFSalvage boron neutron capture therapy for recurrent intracranial malignant meningioma: Case report and literature review.
Medicine (Baltimore)
August 2025
Department of Radiation Oncology, Chi Mei Medical Center, Tainan, Taiwan.
Rationale: Meningiomas are the most common central nervous system tumors in adults, accounting for approximately one-third of the total. Although only 1% to 3% of meningiomas are malignant, these cases exhibit a high degree of aggression and frequent recurrence, resulting in a poor prognosis. There are no accepted treatment standards for salvage re-irradiation.
View Article and Find Full Text PDFPredictors of brachial plexopathy following head and neck reirradiation.
Radiother Oncol
July 2025
Department of Radiation Oncology, The Ohio State University Wexner Medical Center, United States. Electronic address:
Background And Purpose: Reirradiation for recurrent or second primary head and neck cancer (HNC) can result in radiation-induced brachial plexopathy (RIBP), a debilitating side effect. This study aims to identify factors associated with the development of RIBP in patients undergoing reirradiation for recurrent or second primary HNC.
Materials And Methods: This retrospective cohort study included 48 patients treated from 2015 to 2022 at a single National Cancer Institute-Designated Comprehensive Cancer Center, with a median follow-up duration of 22.